News & media
Here you can find our news and media resources. To comply with applicable regulation in Denmark, press releases and company announcements concerning specific medicinal products or investigational candidates in late-stage development are removed from our website within three weeks of publication. Please contact us to request a copy.
-
Zealand Pharma completes registration of capital increase
-
Zealand Pharma announces completion of an upsized equity offering of 8.35 million new ordinary shares raising gross proceeds of USD 1 billion / DKK 7 billion
-
Zealand Pharma announces upsizing of previously announced equity offering from approximately USD 900 million / DKK 6.257 billion to USD 1 billion / DKK 7 billion
-
Zealand Pharma launches equity offering of new shares raising gross proceeds of approximately USD 900 million / DKK 6.257 billion
-
Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose clinical trial with long-acting amylin analog petrelintide
-
Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants
-
Zealand Pharma announces that Boehringer Ingelheim’s survodutide demonstrates breakthrough improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis
-
Zealand Pharma announces that Boehringer Ingelheim will present positive results from Phase 2 trial with survodutide in MASH at EASL
-
Zealand Pharma announces positive CHMP opinion for dasiglucagon for treatment of severe hypoglycemia in diabetes from European Medicines Agency
-
Zealand Pharma to participate in upcoming healthcare investor conferences in June 2024
-
Zealand Pharma major shareholder announcement: Polar Capital
-
Zealand Pharma announces topline results from the mechanistic investigator-led DREAM trial with low doses of GLP-1/GLP-2 receptor dual agonist dapiglutide
Corporate management
-
Adam Steensberg - President and Chief Executive Officer
-
Adam Steensberg - President and Chief Executive Officer
-
Christina Sonnenborg Bredal - Executive Vice President and Chief People Officer
-
David Kendall - Executive Vice President, Research & Development and Chief Medical Officer
-
Henriette Wennicke - Executive Vice President and Chief Financial Officer
-
Ivan Møller - Executive Vice President and Chief Operating Officer
-
Ravinder Chahil - Executive Vice President and General Counsel
Research and development
-
Lab photo
-
Lab photo
-
Lab photo
-
Lab photo
-
Lab photo
-
Lab photo
-
Lab photo
Logos and icons
-
)
Zealand Pharma Logo (RGB)
Stay up-to-date with the latest news from Zealand
Sign-up to receive press releases and company announcements directly to your inbox
Investor and Media contacts
